Klinische studies kinderreumatologie

Overzicht van alle klinische studies van kinderreumatologie

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children under the age of 16. This autoimmune disease is characterised by persistent joint inflammation. The typical signs of joint inflammation are pain, swelling and limitation of movement.. There are several forms of JIA. They are mainly distinguished by the number of joints affected at presentation (e.g oligoarticular – less than 5 joints - or polyarticular JIA – 5 or more joints) and by the presence of additional symptoms such as fever, rash and others (Psoriatric arthritis, systemic JIA). Treatment is based mainly on the use of drugs that inhibit articular and/or systemic inflammation and physiotherapy. The therapeutic possibilities for pediatric rheumatology patients have expended since 2000 (with the introduction of biological therapies). However, some children seem to be "treatment resistant", meaning that the disease is still active and the joints inflamed despite intensive treatment. Therefore, the search of alternative therapies is still needed.

Study to Evaluate the Safety and Efficacy of Baricitinib in Patients with Juvenile Idiopathic Arthritis (Lilly)

Principal Investigator: Prof. Carine Wouters/ Prof. Lien De Somer

JAHV: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA).

JAHX: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA).

JAHU: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less Than 18 Years Old with Systemic Juvenile Idiopathic Arthritis.

Samenvatting

In deze studies worden (s)JIA patiënten gerandomiseerd in de behandelingsgroep met baricitinib of in de placebogroep. Baricitinib is een JAK inhibitor, die een belangrijke rol speelt in de cytokine signaal transductie. Het doel van deze studies is om de doeltreffendheid van baricitinib te evalueren in vergelijking met placebo in JIA (JAHV) en sJIA patiënten (JAHU). JAHX is de open-label opvolgstudie.

Pediatric rheumatologic inflammatory disease (JIR)

Principal Investigators: Prof. Carine Wouters/ Prof. Lien De Somer

Samenvatting

In deze studie worden alle kinderen met een reumatologische inflammatoire ziekte geïncludeerd om gegevens over de eigenschappen, behandelingsrespons en prognose van de ziekte te verzamelen. Het doel van deze observationele cohort studie is om de verschillende ziektebeelden te verduidelijken en de behandeling van deze ziektes te verbeteren.

Laatste aanpassing: 3 maart 2021